Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma
- Citation:
- Am J Clin Oncol vol 37 (4) 369-376
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 2
- Parents:
- 422
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA035267, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, UG1 CA189825, CA-35195, U10 CA037404, U10 CA180821, U10 CA035195, CA-35103, CA-25224, U10 CA035101, U10 CA063849, U10 CA180882, U10 CA035431, UG1 CA189808, CA-37417, CA-35269, CA-35101, U10 CA025224, CA-35267, CA-63849, U10 CA035103
- Corr. Author:
- Authors:
- Roxana S. Dronca Jacob B. Allred Domingo G. Perez Wendy K. Nevala Elizabeth A.T. Lieser Michael Thompson William J. Maples Edward T. Creagan Barbara A. Pockaj Judith S. Kaur Timothy D. Moore Benjamin T. Marchello Svetomir N. Markovic
- Networks:
- Study
- NCCTG-N0675
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- cancer, melanoma, mammalian target of rapamycin (mTOR), angiogenesis, vascular endothelial growth factor (VEGF)